Indonesia Biosimilars Market Outlook to 2028

Indonesia Biosimilars Market Overview

The Indonesia biosimilars market is valued at USD 210 million, based on a five-year historical analysis. This market's growth is driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, alongside rising healthcare costs, which make biosimilars a cost-effective alternative to biologics. Additionally, government policies supporting healthcare infrastructure and the expedited regulatory approval for biosimilars contribute to the market's expansion. The need for affordable therapeutic options in a growing population further drives the biosimilars demand in the country.

Java and Sumatra dominate the biosimilars market in Indonesia, primarily due to their robust healthcare infrastructure and concentration of major pharmaceutical manufacturing facilities. These regions are home to the largest populations in the country, which increases the demand for biosimilar therapies. Moreover, government hospitals and leading private healthcare providers in these areas are focusing on offering cost-effective treatment options, making biosimilars a popular choice. Java, being Indonesia's economic hub, also benefits from higher disposable income, which further fuels market demand.

Indonesias government enforces the TKDN (Domestic Component Level) policy, which mandates that at least 40% of the components used in biosimilars must be sourced locally. This regulation, implemented in 2023, aims to boost local manufacturing and reduce dependence on imports. The TKDN policy has incentivized local pharmaceutical companies to increase production capacity and collaborate with international firms to meet these requirements, further fostering the growth of Indonesia's biosimilars market.

Indonesia Biosimilars Market Segmentation

By Product Type: The market is segmented by product type into oncology biosimilars, autoimmune biosimilars, diabetes biosimilars, and other therapeutic biosimilars. Recently, oncology biosimilars hold a dominant market share in Indonesia under the product type segmentation. This dominance is due to the rising incidence of cancer and the growing need for cost-effective cancer treatments. Biosimilars offer an affordable alternative to branded biologics, making them more accessible to a larger portion of the population.

By Application: The market is segmented by application into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies lead the market under the application segmentation. This is attributed to hospitals being the primary point of care for patients requiring biologics and biosimilars. Furthermore, hospitals in Indonesia are partnering with biosimilar manufacturers to provide affordable treatments to patients, especially those with chronic conditions requiring long-term therapy. The availability of healthcare professionals in hospitals to guide patients on biosimilar use further boosts hospital pharmacies as the dominant distribution channel.

Indonesia Biosimilars Market Competitive Landscape

The Indonesia biosimilars market is dominated by a few key players, including both international pharmaceutical giants and domestic manufacturers. Companies such as Biocon, Pfizer, and Samsung Bioepis are prominent due to their vast portfolios of biosimilars and their strong distribution networks in the region. Local manufacturers are also making significant inroads, benefiting from government support aimed at promoting local production and reducing dependence on imported biologics.

Company

Established

Headquarters

Specialization

Market Presence

R&D Focus

Key Products

Strategic Partnerships

Distribution Strength

Revenue

PT Kalbio Global Medika

2010

Jakarta

Novartis

1996

Switzerland

Sanbe Farma

1975

Jakarta

Roche

1896

Switzerland

Biocon

1978

India

Indonesia Biosimilars Industry Analysis

Growth Drivers

Rising Demand for Cost-effective Biologics: Biosimilars offer an economically viable solution in Indonesia's healthcare system, which is struggling with rising costs of biologic therapies. The World Bank indicates that Indonesias healthcare expenditure reached IDR 1,800 trillion in 2023, with biologics accounting for a substantial portion. Biosimilars provide a cheaper alternative, often priced 30-40% lower than their reference biologics. This price difference is crucial in expanding access to life-saving treatments for underserved populations, helping the government to manage healthcare costs more effectively.

Government Support and Regulatory Approvals: The Indonesian government has been instrumental in fostering biosimilars adoption through regulatory and policy support. In 2024, the National Agency of Drug and Food Control (BPOM) fast-tracked the approval of 15 new biosimilars, allowing for quicker market entry. The governments support is backed by its aim to reduce dependence on expensive imported biologics and promote local manufacturing of biosimilars. Additionally, incentives such as tax exemptions and reduced regulatory barriers have encouraged domestic and foreign pharmaceutical companies to invest in the production and distribution of biosimilars.

Expanding Healthcare Infrastructure: Indonesias healthcare infrastructure is rapidly improving, with the government committing over IDR 300 trillion to healthcare development in 2023. This expansion has led to the construction of more hospitals, clinics, and healthcare facilities, improving access to advanced treatments like biosimilars. By 2024, the number of hospitals in Indonesia is expected to reach 3,500, up from 2,870 in 2021. This improvement in healthcare services has directly contributed to the growing demand for biosimilars, which are essential for treating chronic diseases in these expanding facilities.

Market Challenges

Stringent Regulatory Pathways: The regulatory approval process for biosimilars in Indonesia remains stringent. The National Agency of Drug and Food Control (BPOM) imposes rigorous clinical testing and documentation requirements. On average, it takes 5-7 years for biosimilars to gain full regulatory approval, causing delays in market entry. Moreover, the cost associated with fulfilling these regulatory requirements is often high, adding to the financial burden on manufacturers. This lengthy process discourages smaller companies from entering the market, reducing the overall availability of biosimilars for patients.

High Manufacturing Costs: Manufacturing biosimilars is a complex and expensive process. Although biosimilars are typically less costly than biologics, the development and production still require significant financial resources. In Indonesia, local companies face high operational costs, with biosimilar production costs exceeding IDR 10 billion per batch, owing to the need for specialized facilities and skilled labor. These high costs limit the number of domestic producers, which in turn affects the supply of biosimilars in the Indonesian market.

Indonesia Biosimilars Market Future Outlook

Over the next five years, the Indonesia biosimilars market is expected to grow significantly, driven by government support for healthcare infrastructure, an increasing number of biosimilar approvals, and rising public awareness regarding the affordability of biosimilars compared to branded biologics. Technological advancements in biosimilar production and international collaborations with local manufacturers are also anticipated to fuel market growth. The expansion of healthcare services in rural and underserved areas of Indonesia will further contribute to the growing demand for biosimilars across the country.

Future Market Opportunities

International Biosimilar Launches in Indonesia: Indonesia is becoming an attractive market for global pharmaceutical companies launching biosimilars. In 2024, global giants like Pfizer and Amgen introduced 5 new biosimilars in Indonesia, targeting oncology and autoimmune diseases. This influx of international biosimilars is expected to boost competition and provide patients with more treatment options. The government's commitment to faster regulatory approvals for foreign biosimilars has also contributed to this opportunity, with many more launches expected over the next few years.

Expanding Biosimilar Portfolio by Domestic Companies: Local pharmaceutical companies in Indonesia are expanding their biosimilar portfolios to meet growing demand. PT Kalbe Farma and PT Bio Farma have introduced 3 new biosimilar drugs into the Indonesian market by mid-2024, focusing on oncology and diabetes treatments. These domestic companies are expected to play a vital role in reducing Indonesia's dependency on imported biosimilars and making these treatments more affordable and accessible to local populations. The expansion of domestic portfolios aligns with the governments push to support local production.
Please Note: It will take 5-7 business days to complete the report upon order confirmation